INmune Bio Inc.
INmune Bio Inc. scores highest on Earnings (52) and lowest on Price (29). Its PosiPenta is 45.68 out of 100, around the middle of similar companies.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Details
PPrice
| P/E ratio | -2.18 |
| P/B ratio | 1.99 |
EEarnings
| Trailing EPS | ₹-63.50 |
| Forward EPS | ₹-40.76 |
NNitro
| Price | 138.38 |
| 52-week high | 246.43 |
| 52-week low | 103.31 |
| Fall from 52-week high | 43.8% |
TTorque
| Return on equity (ROE) | -74.82% |
| Debt-to-equity | 0.07 |
AAnchor
| Beta (price swings) | 0.90 |
| Market cap | ₹384 Cr |
| Insider holding | 10.75% |
| Dividend yield | 0.00% |
Figures as used for the week of 24 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is INmune Bio Inc.'s PosiPenta score?
INmune Bio Inc.'s PosiPenta is 45.68 out of 100 for the week of 24 Oct 2026, based on 5 of 5 pillars.
Which PosiPenta pillar is strongest for INmune Bio Inc.?
Earnings (growth), with a score of 52 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for INmune Bio Inc.?
Price (valuation), with a score of 29 out of 100: weaker than most similar companies.
Has INmune Bio Inc.'s PosiPenta changed since last week?
Yes, it fell 1.35 points, from 47.03 to 45.68.
PositoAI is for research and education only and is not investment advice.